This brand name is authorized in Austria, Israel
The drug CANEMES contains one active pharmaceutical ingredient (API):
|
1
Nabilone
UNII 2N4O9L084N - NABILONE
|
|
Nabilone is a synthetic cannabinoid and dibenzopyrane derivative, an analog of dronabinol (also known as tetrahydrocannabinol or THC), the psychoactive ingredient in cannabis with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It has been suggested that nabilone is a highly selective and strong agonist for the cannabinoid receptors CB1 and CB2, both of which are coupled to Gi/o proteins. The CB1 receptors are expressed predominantly in central and peripheral neurons and receptor stimulation has been implicated in the reduction of chemotherapy-induced nausea. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A04AD11 | Nabilone | A Alimentary tract and metabolism → A04 Antiemetics and antinauseants → A04A Antiemetics and antinauseants → A04AD Other antiemetics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 8703 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
